Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21303806 | 0.83 | CARM1 (0.47) | HRH3L3MBTL1L3MBTL3KDM1A | |
| SCHEMBL14824991 | 0.81 | HRH3 (0.56) | HRH3 | |
| SCHEMBL20739932 | 0.80 | HRH3 (0.45) | HRH3L3MBTL1L3MBTL3KDM1ACYP3A4 | |
| SCHEMBL22851679 | 0.80 | HRH3 (0.45) | HRH3L3MBTL1L3MBTL3KDM1ACYP3A4 | |
| SCHEMBL21386205 | 0.79 | HRH3 (0.52) | HRH3L3MBTL1 | |
| SCHEMBL24326956 | 0.77 | HRH3 (0.50) | HRH3L3MBTL1L3MBTL3KDM1A | |
| SCHEMBL7595350 | 0.77 | HRH3 (0.50) | HRH3L3MBTL1L3MBTL3KDM1ACYP3A4 | |
| SCHEMBL23182068 | 0.76 | L3MBTL1 (0.54) | HRH3L3MBTL1L3MBTL3 | |
| SCHEMBL23181938 | 0.75 | HRH3 (0.41) | HRH3L3MBTL1L3MBTL3KDM1ACYP3A4 | |
| SCHEMBL24081401 | 0.75 | HRH3 (0.61) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017044792-A1 | ACETAMIDE THIENOTRIAZOLDIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |